The new TargetSolutions updates enhance usability, streamline firefighter training, and optimize access across all devices.

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Choose from Safety First stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection Essentials ...

Q4 2025 Earnings Call Transcript April 2, 2025 BlackBerry Limited beats earnings expectations. Reported EPS is $0.03, ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

(Gray News) - Some Safety 1st 3-in-1 car seats have been recalled because an incorrect label may result in a child not properly being restrained. The recall includes Safety 1st Comfort Ride 3-in-1 ...

Gene therapy, a technique that is revolutionizing the treatment of multiple genetic conditions, including eye and muscle diseases and blood disorders, requires efficient and specific delivery of the ...

BioSciences announced the first patient has been dosed in the Phase 2 ASCEND study of PCRX-201 for the treatment of ...

due to their efficiency and favorable safety profile. To assist researchers in the selection of the optimal AAV vector for their application, we have generated a detailed map of viral delivery to ...

Get them exclusively at High Dividend Opportunities. Learn More » "Safety first!" – a phrase we've all heard and probably told our kids countless times. But what does it really mean?